Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression

Figure 1

The patient received initial treatment of everolimus 10 mg/d as the third-line chemotherapy. CT scans were taken every 2 months during the initial treatment period. CT scans reveal the diffuse liver metastases before treatment with everolimus (A). After 1 year and 2 months of everolimus 10 mg/d, partial response was achieved (B).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us